Exposure of major cohorts to duvelisib
| Cohort diagnosis . | Total (N = 210), n (%) . | Subjects who began 2/6/12 cycles (28 d) (%) . | Median cycles begun . |
|---|---|---|---|
| iNHL | 31 (14.8) | 27/15/8 (87.1/48.4/25.8) | 5 |
| CLL/SLL (RR) | 55 (26.2) | 54/34/20 (98.2/61.8/36.4) | 6 |
| CLL (TN) | 18 (8.6) | 17/15/12 (94.4/83.3/66.7) | 16 |
| T-cell NHL | 35 (16.7) | 26/11/3 (74.3/31.4/8.6) | 4 |
| Cohort diagnosis . | Total (N = 210), n (%) . | Subjects who began 2/6/12 cycles (28 d) (%) . | Median cycles begun . |
|---|---|---|---|
| iNHL | 31 (14.8) | 27/15/8 (87.1/48.4/25.8) | 5 |
| CLL/SLL (RR) | 55 (26.2) | 54/34/20 (98.2/61.8/36.4) | 6 |
| CLL (TN) | 18 (8.6) | 17/15/12 (94.4/83.3/66.7) | 16 |
| T-cell NHL | 35 (16.7) | 26/11/3 (74.3/31.4/8.6) | 4 |